Click on a company name to read more:
Abcam plc is a producer and distributor of research-grade antibodies and associated products. Its catalog exceeds 45,000 products.
ActiveHealth's CareEnginesm Service is a sophisticated, knowledge-loaded technology platform that utilizes evidence-based medicine to identify and stratify patient risk based upon claims, pharmacy, laboratory and UM data collected from the continuum of care.
TheCareEngine Service combs through high volumes of patient claims, pharmacy, laboratory, and hospital data and applies a series of clinical algorithms, or "Clinical matrices" designed to identify cases in which there may be a problem with the current course of treatment, or a medical problem that is not being addressed.
InvestCare Partners exited its investment in ActiveHealth in May 2005.
Altacor is an Ophthalmology Specialty Pharmaceutical Company which develops and markets differentiated products directed to the needs of both ophthalmologists and patients. Altacor uses its drug development skills and in depth market knowledge to build a portfolio of high quality, differentiated prescription medicines that set new standards in the sector. Altacor's pipeline consists of development and in-licensed products which address Ocular Surface Disease, Ocular Infection and Glaucoma.
AMICAS is a seasoned Healthcare Information Technology (HIT) company that develops, markets and sells the first complete Internet-based alternative to medical X-ray film. AMICAS software only solution competes in the space known as Picture Archive and Communication (PAC) systems.
During the past five years AMICAS has gained market share with a customer base approaching 100 that includes Massachusetts General Hospital, New York’s Columbia Presbyterian Medical Center, New York Weill Cornell Medical Center, Boston Medical Center, University of Chicago Hospitals, Michigan State University and dozens of other leading healthcare facilities.
Investcare Partners exited its investment in Amicas in November 2003.
Amura is a structure-based drug discovery business specialising in diseases such as osteoporosis, osteoarthritis, bone metastasis, autoimmunity, chronic pain and malaria. Amura has aproprietary technology platform (AMcore™ 
) that provides a turnkey solution for the discovery of small-molecule inhibitors against cysteine peptidases (cathepsin enzymes); which are commercially attractive therapeutic targets. Amura compounds possess highly desirable drug-like properties; thereby facilitating therapid and innovative discovery of orally active pharmaceutical ingredients across several disease areas.
Animas Corp. provides products and services for patients with Type 1 diabetes to better manage their disease, reduce long-term morbidity,and to lower costs to the patients and healthcare system. The company'sprimary efforts are focused on making diabetes management easier for both the patient and healthcare provider through product innovation, customer support, and superior customer education.
Animas launched its first product, the R1000 insulin infusion pump in July 2000 and its next generation pump, the IR1000, in September 2002. Additional products under development include: the ezManager softwaresystem, novel insulin infusion sets and an implantable continuous glucose monitor. The long-term vision of the company is to ultimately combine the pump and sensor in a single closed loop device.
InvestCare Partners exited its investment in Animas in December 2005.
BioVex is a biotechnology company focused on the development and commercialization of a new class of potent biologics for the treatment of cancer and prevention of infectious disease. The Company’s lead cancer technology platform, OncoVEX GM-CSF is a first-in-class oncolytic, or cancer destroying virus technology. OncoVEX GM-CSF worksby: replicating and spreading within solid tumors, causing the death of cancer cells; while stimulating the immune system to destroy metastatic deposits.
Community Pharmacy Ltd (“CPL”) is a newly established chain of pharmacies, particularly focused on GP centre- based pharmacies.
Craneware, Inc. is a leading supplier of business intelligence and revenue cycle software that provides clients with charge master management software and products designed to optimize legitimate reimbursements and assist in managing the revenue cycle through better information, workflow, pricing strategy, capture of lost revenue and best practice modeling.
Crothall is a principal supplier of specialized facilities management services to hospitals, universities and commercial clients throughout the United States and Canada.
By providingspecialized management expertise in the areas of facilities engineering, housekeeping, laundry and linen, patient transportation, and energy and asset management.
Investcare Partners exited its Crothall investment in August 2001.
Delphinus Medical Technologies, a spinout from the Barbara Ann Karmanos Cancer Institute in Detroit, is the developer of SoftVue, an alternative to mammography for breast cancer detection, risk evaluation and treatment monitoring.
The SoftVue system does not involve radiation or compression and can effectively differentiate benign from malignant masses in breasts, helping to reduce the number of false positives and thereby reduce unnecessary biopsies. Unlike mammography the breast is submerged in warm water and an ultrasound ring surrounds the breast and captures detailed, three-dimensional images through the use of sound waves. The results are similar to MRI; however the SoftVue system takes only minutes and costs much less. The system is also able to perform repeated imaging, a necessary tool for treatment monitoring.
In addition, through its three-dimensional capabilities, SoftVue can accurately measure breast density, a known risk factor for developing breast cancer, as well as detect many early stages of breast cancer in women with dense breast tissue, which is often not picked up by mammography.
www.delphinusmt.com
deltaDOT Ltd. is a Life Science company focused on developing and commercializing innovative enabling technologies for the separation and analysis of biomolecules. deltaDOT was founded in 2000 and is a spinout from Imperial College of Science, Technology and Medicine, London. The company is focused on harnessing the cutting edge technologies developed in the Department of High Energy Physics and their application to biomolecular separation and analysis.
deltaDOT'score label free analysis technology, coupled with proprietary software algorithms, forms the technical basis of deltaDOT's products. deltaDOTlabel free technology enables higher quality and faster separations from existing separation technologies. The increased performance enabling the direct monitoring of unlabelled biomolecules, reducing the cost per analysis compared to conventional methods. deltaDOT addresses biomolecular separation applications within pharmaceutical, biotechnology, biodefence, food and drink quality, forensic science, diagnostic and academic markets.
Digital Healthcare delivers software solutions that address some ofthe World's fastest growing healthcare issues. Founded to provide image management and storage solutions for the Ophthalmology sector, the company has extended its product range and expanded into new International territories based on its core competencies in Clinical Information and Patient Care Management and is now a leading provider to the NHS in the UK, a major supplier to US physicians and has solutions in use within some of the Worlds' leading Eye Institutions.
gloStream provides doctors with certified, voice-enabled electronic medical record and practice management solutions delivered and supported through a nationwide community of local technology partners. gloStream products are secure, easy-to-use applications and the only solutions on the market with Microsoft Office built right in. gloStream partners leverage gloDNA (gloStream Detailed Needs Analysis), an innovative implementation process that allows gloStream to offer its 15-Day Money Back Success Guarantee. gloStream guarantees that if it can't get a practice back to full patient load within 15 days of implementing gloEMR, the company will provide a full refund for all gloStream software and services.
Health Hero Network develops and markets a technology platform for remote patient monitoring. Leading healthcare product and service providers offer programs based on the Health Hero platform® to communicate with, educate, and monitor patients with a variety of conditions including heart disease, diabetes, respiratory disease, mental health, and post-acute care. By identifying changes in a patient's health condition more rapidly, The Health Hero platform enables caregivers to focus attention on those most in need of intervention, a factor that has a tremendous impact on reducing healthcare spending while improving quality of care. The company alsois licensing its platform to medical device and pharmaceutical companies seeking to enable new service and revenue opportunities from disease management or to enhance clinical research.
The company has protected its pioneering work in patient communications technologies over the past decade with a portfolio of more than 30 patents.
InvestCare Partners exited its investment in Health Hero Network in December 2007.
Immunodiagnostic Systems Holdings plc (IDS) is dedicated to the development and provision of innovative immuno assays for use in clinical and research laboratories worldwide. The Company is focused on creating and sustaining its position as a leading specialist inin-vitro diagnostics, building an enviable capability in de novo product design, development, manufacture and marketing.
InforSense provides a suite of highly agile, predictive and visualenterprise business intelligence and reporting software. InforSense was founded in 1999 to commercialize pioneering, award-winning technology in the fields of High Performance Computing and Large Scale Data Mining developed at Imperial College, London.
InforSense’s core expertise lies in the development of a generic, horizontal, high performance business and scientific intelligence and Web-based reporting platform. This platform enables organizations to integrate, automate and visualize data sources, information and analysis processes to deliver significantly improved productivity, performance and breakthrough predictive insights.
Intervention Insights provides actionable strategies that assist community oncologists in developing personalized treatments for their patients. By analyzing cancerous tissue, Intervention Insights generate a genomic picture of over 20,000 genes and corresponding molecular pathways that uniquely define a person's cancer and the drugs that target them. The company delivers this information to its frontline oncology partners who can quickly review hundreds of drugs which specifically target the molecular basis of a person's cancer. The technology, OncInsights, is commercially available and used by an expanding network of community oncologists.
www.interventioninsights.com
Bold indicates a current portfolio company
InTouch Health, Inc., founded by medical robotics pioneer YulunWang, Ph.D., provides technology solutions which dramatically increase the effectiveness of healthcare professionals. The company is addressing the impending demographic crisis in senior care support by pioneering the use of Remote Presence in healthcare with its "Companion" system. Through a proprietary communications and mobilerobotic platform, caregiving experts are projected to another settingwhere a patient or caregiver is located to provide care, coach andtrain staff, or monitor healthcare services. The InTouch Healthsolution leverages the time and expertise of healthcare professionals across multiple care facilities, improving the efficiency and effectiveness of care delivery.
Applications for InTouchHealth's innovative medical technology include remote patient monitoring by experts in other parts of the country and shoring-up scarce nursing resources. There are currently over 400,000 unfillednursing positions in the country.
IS Pharma (International Speciality Pharmaceuticals) develops, acquires and commercializes late-stage pharmaceuticals and medical devices, focusing in critical care, oncology and neurology. Based in the UK, IS Pharma commercializes its portfolio in the UK directly and internationally through a strong network of distributors.
Medsite is an e-marketing service provider to pharmaceutical and healthcare companies. Through its Internet-based programs, Medsite connects companies with its extensive healthcare provider database. TheCompany's primary service, Medsite Rewards Program(tm), has reached over 400,000 physicians.
Medsite uses the power of the Internet to provide a full suite of online marketing and educational services that broaden reach, cement relationships, and deliver rewards to physicians. Over the years, Medsite has forged strong relationships with physicians by offering user-friendly, high quality products on itsWeb site, and by offering medically relevant gifts through MedsiteRewards. Medsite has reached over 200,000 physicians through its Medsite Rewards program, and has transactional online relationships with over 125,000 physicians and 50,000 medical students.
InvestCare Partners exited its investment in Medsite in September 2006.
MedVantx has developed a comprehensive point-of-care pharmaceutical management and automated medication dispensing system. The Company's web-enabled system automates the distribution chain and control of physician-administered medications, drug company samples, OTC products and first prescription medications at the point-of-care.
TheMedVantx approach is based on turning complex processes into streamlined systems that provide physician convenience and high-qualitycare for the patient. It delivers prescriptions in the healthcare provider's office, at the point of diagnosis, exactly as the physician recommended. This provides the opportunity to discuss dosing, potential side effects, and any specific recommendations about a particular drug.
MedVantxalso provides patient benefit information to the physician at the point of prescription. Information that helps physicians prospectively choose the right medication - formulary compliant and clinically safe. It is compatible with many e-Prescribing tools.
Molecular Imaging, Inc. is a specialty contract research organization (CRO) located in Ann Arbor, Michigan. Molecular Imaging employs a wide array of imaging technologies, including MRI, micro-CT, micro-PET and optical (two-dimensional and molecular fluorescence tomography) to quantitatively measure response to therapy at anatomical, functional and molecular levels. Molecular Imaging also conducts applications research to develop and optimize the use of imaging and actively seeks collaborations to further advance imaging in the field of drug discovery.
www.interventioninsights.com
MRS Partners provides a full range of the highest quality, outcome oriented, physical therapy and occupational therapy for orthopedic injuries, work related injuries, sports injuries and various neurological and neuromuscular conditions. The rehabilitation process is an individual, personalized, goal-oriented program with an emphasis on restoring normal function through quality therapy services while minimizing costs. The Company’s therapy services are designed to help patients regain normal mobility and strength, and to provide long term pain relief, thus allowing them to get back to their normal activities as quickly as possible. Therapists use state of the art technology and techniques and are highly trained to meet the specific needs of their patients.
www.mrspt.com
Omni Dental Sciences Ltd is the holding company for two trading companies — Oraldent Limited which develops and sells oral care products and Professional Dental Supplies Ltd which sells crossinfection products.The core business is to provide high added value dental products where there is a proven market and scientific supportfor the products.
Onyx provides a wide range of chemical services to the life sciences and pharmaceutical industries. Its key focus is scaling up the synthesis of new chemical entities for drug development. OnyxScientific is one of the fastest growing pharmaceutical service companies in the UK. Onyx has more than 40 expert scientists specializing in drug development from medicinal chemistry to earlystage GMP production. The company’s chemistry expertise has an industry leading reputation.
Beringea exited its investment in Onyx in September 2011.
Pioneer Surgical Technology, Inc. is a dynamic medical device firm with a full line of cutting-edge motion preservation devices, either available commercially in Europe or under clinical evaluation in theU.S. Pioneer’s signature articulating P3™ Technology — PioneerPEEK-on-PEEK, in its NuBac™ disc arthroplasty system, BacJac™interspinous decompression system, and NuNec™ artificial cervical disc, is the most technologically advanced in the industry. Currently, Pioneer offers a diverse portfolio of next generation spinal fusion devices.
Pioneer’s focus on innovation has resulted in over 100 U.S. and Foreign patents with numerous patents pending. The company established a Biologics Division following two acquisitions in2007. Pioneer Orthobiologics is developing a rich pipeline of productsindicated for a variety of spinal and orthopaedic applications. Pioneer focuses on developing products which are easier and faster for thesurgeon, cost effective for the health care system, and provide better patient outcomes.
Plum Baby is a UK premium organic baby food brand which is committed to providing "real food" for babies and parents.
Beringea exited its investment in Plum Baby in June 2010.
PolyTherics is a biopharmaceutical company that enables the development of better biopharmaceuticals and has developed three proprietary technologies for attaching the polymer poly(ethylene glycol) (PEG) to any therapeutic peptide or protein in a targeted fashion. PEGylation slows elimination from the body, thereby improving half-life and potentially reducing drug treatment frequency, decreasing side effects and improving patient compliance.
PEGylated products derived from PolyTherics’ technologies are more homogeneous than those derived from traditional methods, resulting in reduced complexity of downstream processing, more consistent product quality and cost-effective manufacture. PEGylation is an established method for improving drugs and ten PEGylated products are already approved for therapeutic use worldwide.
PolyTherics commercial relationships include an option and licence agreement concluded in May 2011 for the development by Nuron Biotech Inc. (USA) for the development of a long-acting interferon utilising the TheraPEG™ technology for the treatment of multiple sclerosis.
www.polytherics.co.uk
Population Genetics Technologies (PGT) Ltd is creating new paradigms for performing large-scale population genetics studies. This novel technology, conceived by Nobel laureate Professor Sydney Brenner, samples large populations to identify the genetic variation responsible for human disease and drug response.
Ranir manufactures and markets consumer oral care products in North America. It offers manual and power toothbrushes, dental floss and flossers, tooth whiteners, trial-sized products, travel kits, and accessories to retailers as well as branded contract manufacturing customers.
Sinclair Pharma plc is an international specialty pharmaceutical company with proven expertise in acquiring or developing commercially attractive and under valued products, registering these products and bringing them to market in a short time frame. The company focuses on niche therapeutic areas and its current portfolio includes products in dermatology and oral health .
The Steribottle Group has, after several years of development, now launched the Steri-Bottle, the world's first ready-to-use, sterile, disposable and affordable baby feeding bottle. It's made of safe plastic, and it comes complete with a special teat all pre-sterilized and ready to use. Feeding is now as simple as opening a fresh bottle, filling with chosen feed, feeding the baby and throwing away the bottle when finished.
The Steri-bottle teat has a noticeably warm and soft feel. Available in 'fast' and 'medium' flow versions, it incorporates a clever little valve that lets in just the right amount of air, allowing your baby to feed comfortably without accumulating excess wind. Steri-bottle has a helpful wise mouth for expressing breastmilk. The Steri-daptor adaptor fits one popular breast-pump, and will be available for most others. Steri-bottle can be used to store milk in your fridge or freezer without the danger of cracking.
TheSteri-bottle represents a fundamental development and paradigm shift inthe FMCG (fast-moving consumer goods) marketplace that has the potential to become as ubiquitous as the disposable nappy. TheSteri-bottle has been developed over the past five years from an idea into a complete business platform being commercialized internationally.
Vectura Group plc is a product development company focused on the development of inhaled therapies principally for the treatment of respiratory diseases. Vectura develops products to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD)and cystic fibrosis (CF). The company also develops products for non-respiratory diseases, where optimized delivery via the lungs could provide significant benefits, such as a rapid onset of action, improved efficacy and improved tolerability compared with current therapies.
Xanitos is a provider of outsourced hospital housekeeping services across the United States. The company’s services include daily and post-discharge cleaning of patient rooms, cleaning and maintenance of flooring in common areas and passageways, and responding to situational cleaning needs. The company’s proprietary patented vacuum-cart and patent-pending XRO Team System improves productivity, significantly reduces the risk of hospital acquired infections, raises HCAHPS scores, and reduces bed turnaround time.
www.xanitos.com
Young Innovations develops, manufactures and markets supplies and equipment used by dentists, dental hygienists, dental sssistants and consumers. The Company's consumables product offering includes disposable and metal prophy angles, prophy cups and brushes, dental micro-applicators, moisture control products, infection control products, dental handpieces (drills) and related components, endodontic systems, orthodontic toothbrushes, flavored examination gloves, children's toothbrushes, and children's toothpastes. In addition, the Company offers a line of diagnostic products that includes panoramic X-ray machines and related supplies. The Company believes it is a leading U.S. manufacturer or distributor of prophy angles and cups, liquid surface disinfectants, dental micro-applicators and obturation units designed for warm, vertical condensation.
www.ydnt.com
